Core Viewpoint - Jinhe Biology (002688.SZ) expects a net profit increase of 40%-55% for the first half of 2025, projecting a profit range of 127 million to 141 million yuan compared to the same period last year [1] Group 1: Financial Performance - The expected net profit for the first half of 2025 is between 127 million and 141 million yuan, indicating a growth of 40%-55% year-on-year [1] - The growth is attributed to strong sales in the veterinary chemical drug segment, particularly the main product, Chlortetracycline, which saw increased sales in both domestic and overseas markets [1] Group 2: Operational Highlights - The overseas market sales have continued to grow, contributing positively to overall performance [1] - The completion of the sixth phase project has increased production capacity, ensuring supply meets demand and generating additional profits [1] Group 3: Sector Contributions - The agricultural product processing segment benefited from a decline in corn prices, which also contributed to the overall performance improvement [1]